Application of Prevention of Nuclear Export of CRM1-Dependent Proteins for the Treatment of Calcific Aortic Valve Disease
- 詳細技術說明
- None
- *Abstract
-
Over 80,000 Americans suffer from calcific aortic valve disease each year. Surgical intervention is the only effective treatment for calcific aortic valve disease and no pharmacological therapies exist largely due to the poor understanding of disease pathogenesis. Researchers at Nationwide Children’s Hospital have developed a novel method for attenuating calcification by preventing nuclear export of CRM1-dependent proteins from heart valve interstitial cells. This technology will drive design and development of new mechanistic-based anti-calcification therapies beyond surgical intervention.
- *Inquiry
- Andrew CorrisThe Research Institute at Nationwide Children’s HospitalOffice of Technology Commercialization700 Children’s DriveColumbus, OH 43205T: (614) 355-1604 F: (614) 722-2716Andrew.Corris@nationwidechildrens.org
- *IP Issue Date
- None
- *IP Type
- Other Patent
- 國家
- Not Available
- 申請號碼
- None
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
